Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 296 entries
View as:

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Phase: N/A Priority: Normal
NCT ID: NCT03529110 Org: User:
Start: 08/09/18 End: 06/01/25 Due: 06/01/26

Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings

Phase: N/A Priority: Normal
NCT ID: NCT05025722 Org: User:
Start: 08/30/21 End: 08/11/22 Due: 08/11/23

A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT05638802 Org: User:
Start: 06/07/23 End: 04/01/25 Due: 04/01/26

Chemotherapy in Treating Patients Who Have Hematologic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00004047 Org: User:
Start: 06/30/99 End: 04/30/05 Due: 04/30/06

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China

Phase: N/A Priority: Normal
NCT ID: NCT06846996 Org: User:
Start: 02/27/25 End: 07/31/27 Due: 07/31/28

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03505710 Org: User:
Start: 05/21/18 End: 04/17/24 Due: 04/17/25

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04042701 Org: User:
Start: 02/10/20 End: 08/01/25 Due: 08/01/26

A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05583669 Org: User:
Start: 11/08/22 End: 05/11/23 Due: 05/11/24

Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04744831 Org: User:
Start: 03/05/21 End: 10/08/24 Due: 10/08/25

A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT01790503 Org: User:
Start: 07/18/13 End: 03/04/20 Due: 03/04/21

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Phase: N/A Priority: Normal
NCT ID: NCT04526691 Org: User:
Start: 09/15/20 End: 04/15/26 Due: 04/15/27

Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.

Phase: N/A Priority: Normal
NCT ID: NCT00151788 Org: User:
Start: 02/29/04 End: 03/31/06 Due: 03/31/07

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04619004 Org: User:
Start: 02/02/21 End: 01/30/26 Due: 01/30/27

Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)

Phase: N/A Priority: Normal
NCT ID: NCT04033094 Org: User:
Start: 10/16/17 End: 12/31/20 Due: 12/31/21

Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00151762 Org: User:
Start: 12/31/04 End: 07/31/07 Due: 07/31/08

Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.

Phase: N/A Priority: Normal
NCT ID: NCT00570739 Org: User:
Start: 11/30/07 End: 05/31/09 Due: 05/31/10

An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia

Phase: N/A Priority: Normal
NCT ID: NCT02234583 Org: User:
Start: 02/04/15 End: 04/19/17 Due: 04/19/18

Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT06740799 Org: User:
Start: 09/30/24 End: 06/30/25 Due: 06/30/26

Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917

Phase: N/A Priority: Normal
NCT ID: NCT00290940 Org: User:
Start: 01/31/06 End: 04/30/07 Due: 04/30/08

Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease

Phase: N/A Priority: Normal
NCT ID: NCT01587651 Org: User:
Start: 03/31/12 End: 02/28/13 Due: 02/28/14

A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05388903 Org: User:
Start: 06/20/22 End: 01/26/23 Due: 01/26/24

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

Phase: N/A Priority: Normal
NCT ID: NCT06578247 Org: User:
Start: 11/19/24 End: 06/26/30 Due: 06/26/31

Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02560688 Org: User:
Start: 12/31/15 End: 03/31/16 Due: 03/31/17

A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks.

Phase: N/A Priority: Normal
NCT ID: NCT00755352 Org: User:
Start: 11/30/02 End: 04/30/05 Due: 04/30/06

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06161025 Org: User:
Start: 02/27/24 End: 12/31/29 Due: 12/31/30